Name | Tranylcypromine hydrochloride,(±)-trans-2-Phenylcyclopropylaminehydrochloride |
---|---|
Synonyms |
(1R,2S)-2-Phenylcyclopropanamine hydrochloride (1:1)
(1R,2S)-tranylcypromine hydrochloride Cyclopropanamine, 2-phenyl-, (1R,2S)-, hydrochloride (1:1) trans-2-Phenylcyclopropylamine hydrochloride Tranylcypromine hydrochloride trans-2-Phenylcyclopropanamine hydrochloride MFCD00063602 |
Description | Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[1][2][3]. |
---|---|
Related Catalog | |
Target |
MAO-A:2.3 μM (IC50) MAO-B:0.95 μM (IC50) |
In Vitro | Tranylcypromine hydrochlorid (50 μM-5 mM; 1 h or 12-14 h) inhibits histone and nucleosomal demethylation[1]. Tranylcypromine hydrochlorid (2 μM; 3 h) shows a specific derepression of OCT4 transcription[1]. Tranylcypromine hydrochlorid (0-100 μM; 15 min) shows IC50 values of 20.7, 2.3 and 0.95 μM for LSD1, MAO A and MAO B, respectively[2]. Tranylcypromine hydrochlorid (0-800 μM) shows Ki values of 242.7, 101.9 and 16 μM for LSD1, MAO A and MAO B, respectively[2]. Western Blot Analysis[1] Cell Line: Sf21 insect cell line Concentration: 50 μM, 200 μM, 1 mM and 5 mM Incubation Time: 12-14 hours or 1 hour Result: Showed inhibitory activities of histone H3K4 demethylation and nucleosomal demethylation. RT-PCR[1] Cell Line: P19 EC cell line Concentration: 2 μM Incubation Time: 3 hours Result: Decreased Oct4 mRNA levels. |
In Vivo | Tranylcypromine hydrochlorid (3 mg/kg; i.p. once daily for 3 days) decreases LPS-mediated microglial activation and proinflammatory cytokine COX-2 and IL-6 levels in wild-type mice[3]. Tranylcypromine hydrochlorid (3 mg/kg; i.p. once daily for 7 days) down-regulates Aβ-mediate microglial activation in 5xFAD mice[3]. Animal Model: Wild-type mice[3] Dosage: 3 mg/kg Administration: Intraperitoneal injection; 3 mg/kg once daily for 3 days Result: Significantly down-regulated LPS-stimulated microglial activation in the cortex and Hippocampus, and LPS-induced astrocyte activation only in the cortex. Reduced LPS-induced COX-2 levels in hippocampus CA1, decreased LPS-evoked IL-6 levels in the cortex and hippocampus CA1 and suppressed LPS-mediated IL-1β levels in the cortex. Animal Model: 5xFAD mice[3] Dosage: 3 mg/kg Administration: Intraperitoneal injection; 3 mg/kg once daily for 7 days Result: Differentially regulated microglial and astrocyte activation in this mouse model of AD. |
References |
Boiling Point | 218.3ºC at 760mmHg |
---|---|
Melting Point | 162-169ºC(lit.) |
Molecular Formula | C9H12ClN |
Molecular Weight | 169.651 |
Flash Point | 90.8ºC |
Exact Mass | 169.065826 |
PSA | 26.02000 |
LogP | 3.00350 |
Appearance | Powder or Chunks | White to light beige |
Vapour Pressure | 0.127mmHg at 25°C |
Storage condition | 2-8°C |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302-H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Hazard Codes | T: Toxic; |
Risk Phrases | R36/37/38 |
Safety Phrases | 45-36/37/39-26 |
RIDADR | UN 3249 |
WGK Germany | 3 |
Packaging Group | III |
Hazard Class | 6.1(b) |
HS Code | 2921499090 |
~% 1986-47-6 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 7 p. 1485 - 1493 |
~% 1986-47-6 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 7 p. 1485 - 1493 |
~% 1986-47-6 |
Literature: Journal of Medicinal Chemistry, , vol. 39, # 7 p. 1485 - 1493 |
Precursor 3 | |
---|---|
DownStream 4 | |
HS Code | 2921499090 |
---|---|
Summary | 2921499090 other aromatic monoamines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |